• Product NameMontelukast
  • CasNo. 158966-92-8
  • MFC35H36ClNO3S
  • MW586.195
  • Purity
  • Appearance
  • Packing
  • Contact usInquiry

Product Details

CasNo: 158966-92-8

MF: C35H36ClNO3S

Cosmetics Grade Montelukast 158966-92-8 For Sale with Good Price

  • Molecular Formula:C35H36ClNO3S
  • Molecular Weight:586.195
  • Vapor Pressure:1.17E-23mmHg at 25°C 
  • Melting Point:145-148 °C(Solv: toluene (108-88-3); methanol (67-56-1)) 
  • Refractive Index:1.677 
  • Boiling Point:750.45 °C at 760 mmHg 
  • PKA:4.76±0.10(Predicted) 
  • Flash Point:407.658 °C 
  • Density:1.272 g/cm3 

Montelukast(Cas 158966-92-8) Usage

Therapeutic Function

Anti-asthmatic

Mechanism of action

Montelukast was developed from other weakly antagonistic quinoline derivatives. A number of changes can be made to the structure without the loss of activity. These include changing the double bond between the two aromatic rings to an ether linkage, reducing the quinoline ring, changing the chlorine to a fluorine, and/or exchanging the sulfur for an amide group.

Pharmacokinetics

Montelukast is a high-affinity, selective antagonist of the cysLT1 receptor. It is rapidly absorbed orally, with a bioavailability of 64%. Montelukast is 99% bound to plasma proteins and is extensively metabolized in the liver by CYP3A4 and CYP2C9 to oxidated products. CYP3A4 oxidizes the sulfur and the C-21 benzylic carbon, whereas CYP2C9 is selectively responsible for the methyl hydroxylation.

Side effects

Montelukast did not demonstrate any significant adverse effects greater than placebo in clinical trials; however, because it is metabolized by the cytochrome P450 (CYP450) enzymes, its plasma levels should be monitored when coadministered with CYP450-inducing drugs, such as phenobarbital, rifampin, and phenytoin.

Drug interactions

Potentially hazardous interactions with other drugs None known

Metabolism

Extensively metabolised in the liver by cytochrome P450 isoenzymes CYP3A4, CYP2A6, and CYP2C9. Excreted principally in the faeces via the bile. Metabolites have minimal therapeutic activity.

InChI:InChI=1/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/t32-/m1/s1

158966-92-8 Relevant articles

Montelukast sodium intermediate compound

-

Paragraph 0066; 0067, (2020/12/08)

The invention provides a novel monteluka...

Montelukast sodium intermediate and preparation method and application thereof

-

, (2017/08/31)

The invention relates to a series of nov...

Production of montelukast

-

Paragraph 0009; 0019; 0023, (2017/08/02)

PROBLEM TO BE SOLVED: To provide a metho...

The crystal manufacturing method [...]

-

Paragraph 0056, (2017/12/27)

PROBLEM TO BE SOLVED: To provide a metho...

158966-92-8 Process route

2-(1-((((R)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)sulfanyl)methyl)cyclopropyl)acetonitrile
866923-62-8

2-(1-((((R)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)sulfanyl)methyl)cyclopropyl)acetonitrile

montelukast
158966-92-8

montelukast

Conditions
Conditions Yield
2-(1-((((R)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)sulfanyl)methyl)cyclopropyl)acetonitrile; With sodium hydroxide; ethanol; water; for 15h; Heating / reflux;
With acetic acid; In ethanol; water; toluene; Product distribution / selectivity;
91%
2-(1-((((R)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)sulfanyl)methyl)cyclopropyl)acetonitrile; With sodium hydroxide; ethanol; water; for 30h; Heating / reflux;
With water; acetic acid; In toluene; for 0.5h; pH=5.6; Product distribution / selectivity;
86%
2-(1-((((R)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)sulfanyl)methyl)cyclopropyl)acetonitrile; With sodium hydroxide; water; tetrabutylammomium bromide; In toluene; at 120 ℃; for 168h;
With acetic acid; In water; toluene; Product distribution / selectivity;
83%
2-(1-((((R)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)sulfanyl)methyl)cyclopropyl)acetonitrile; With sodium hydroxide; ethanol; water; for 25h; Heating / reflux;
With acetic acid; In water; toluene; for 0.5h; pH=5 - 5.5; Product distribution / selectivity;
2-(1-((((R)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)sulfanyl)methyl)cyclopropyl)acetonitrile; With sodium hydroxide; water; at 111 - 130 ℃; for 20h;
With water; acetic acid; at 90 ℃; for 1h; pH=~ 11; Product distribution / selectivity;
With caustic lye; at 120 ℃; for 12h;
1.32 g
(1-{1-(R)-(3-bromophenyl)-3-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-propylsulfanylmethyl}-cyclopropyl)-acetic acid
1015076-80-8

(1-{1-(R)-(3-bromophenyl)-3-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-propylsulfanylmethyl}-cyclopropyl)-acetic acid

7-chloro-2-ethenylquinoline
177748-00-4

7-chloro-2-ethenylquinoline

montelukast
158966-92-8

montelukast

Conditions
Conditions Yield
With triethylamine; palladium diacetate; tris-(o-tolyl)phosphine; In N,N-dimethyl-formamide; at 100 ℃; for 4.25h;
85%
With triethylamine; palladium diacetate; tris-(o-tolyl)phosphine; In N,N-dimethyl-formamide; at 100 ℃; for 4h; Product distribution / selectivity;
67.6%
(1-{1-(R)-(3-bromophenyl)-3-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-propylsulfanylmethyl}-cyclopropyl)-acetic acid; 7-chloro-2-ethenylquinoline; With triethylamine; palladium diacetate; tris-(o-tolyl)phosphine; In N,N-dimethyl-formamide; at 100 ℃; for 4h;
With water; citric acid; In ethyl acetate; N,N-dimethyl-formamide; toluene; pH=3 - 4;
(1-{1-(R)-(3-bromophenyl)-3-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-propylsulfanylmethyl}-cyclopropyl)-acetic acid; 7-chloro-2-ethenylquinoline; palladium diacetate; tris-(o-tolyl)phosphine; In N,N-dimethyl-formamide; for 0.25h;
With triethylamine; In N,N-dimethyl-formamide; at 100 ℃; for 4h;
With citric acid; In water; ethyl acetate; N,N-dimethyl-formamide; toluene; pH=3 - 4;

158966-92-8 Upstream products

  • 851755-56-1
    851755-56-1

    [R,E]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(methoxycarbonyl)phenyl]propyl]thio]methyl]-cyclopropane acetic acid

  • 676-58-4
    676-58-4

    methylmagnesium chloride

  • 807638-71-7
    807638-71-7

    2-[2-[3(S)-[3-[(1E)-2-(7-chloroquinoline-2-yl)ethenyl]phenyl]-3-methanesulfonyloxypropyl]phenyl]-2-propanol

  • 947370-34-5
    947370-34-5

    (R-(E))-1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid cyclooctylammonium salt

158966-92-8 Downstream products

  • 151767-02-1
    151767-02-1

    Montelukast sodium

  • 1005743-12-3
    1005743-12-3

    1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid tris(hydroxymethyl)aminomethane salt

  • 1005743-14-5
    1005743-14-5

    1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid L-(+)-treo-2-amino-1-phenyl-1,3-propanediol salt

  • 1005743-16-7
    1005743-16-7

    1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid L-(+)-α-phenylglycinol salt

Relevant Products